| Name | Title | Contact Details |
|---|
Open MRI and CT Specialists is a Stockbridge, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Renaissance RX is on the forefront of the new era of personalized medicine. The laboratory provides Pharmacogenetic Testing and Advanced Toxicology to give doctors unique insight into each individual patient with the most accurate and actionable information. The results are healthier patients and more successful medical practices. To compliment lab services and help ensure drug adherence, Renaissance RX offers access to its online medication portal and the Virtual PharmD Intelligence Engine.
Puerto Rico Labor and Human Resources is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders
Prothena Corporation plc (Nasdaq: PRTA) Prothena is a global biotechnology company seeking to fundamentally alter the course of progressive diseases. We are a late-stage clinical company focused on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding and inflammatory cell adhesion disorders. Our team has a recognized track record both for profound scientific discoveries and for the development of therapeutics that have become leading commercial products in their respective therapeutic categories. Prothena`s pipeline focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins and our antibody-based product candidates target a number of potential indications, including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), ATTR amyloidosis (PRX004), and novel cell adhesion targets involved in psoriasis, psoriatic arthritis and other inflammatory diseases (PRX003). Prior to December 2012, Prothena’s business operated as part of Elan Corporation, plc. Prothena’s business consists of a substantial portion of Elan’s former drug discovery business platform. After the separation from Elan and the related distribution of our ordinary shares to Elan’s stockholders, our ordinary shares began trading on The Nasdaq Global Market under the symbol “PRTA” on December 21, 2012.